Gabriel Fahel, a Senior Officer, acquired 9,000 Common Shares on a direct ownership basis at a price of $2.500 on August 17th, 2021. The insider also acquired 1,200 Common Shares on an indirect ownership basis for registered holder Child's Registered Account at a price of $2.500 on August 17th, 2021. The insider also acquired 50,000 Common Shares on an indirect ownership basis for registered holder Imeix Inc. at a price of $2.520 on August 17th, 2021. This represents a $151,500 investment into the company's shares and an account share holdings change of greater than 100%.
Cybin is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Cybin Inc., formerly Clarmin Explorations Inc., is a Canada-based life sciences company. The Company is focused on developing psychedelic pharmaceutical and non-psychedelic nutraceutical-based products. Its subsidiaries include Natures Journey Inc. and Serenity Life Sciences Inc. Serenity Life Sciences Inc. is focused on research and development of psilocybin-based medications. Natures Journey Inc. operates the Journey brand, which specializes in developing medicinal mushroom products. It has a drug delivery platform developed to administer psychedelic therapies and bypass liver metabolism. The Company also focus is on the development of treatment regimens consisting of psychedelic molecules and related clinical protocols.
No Comments